Notable Labs, Ltd. (NTBL) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Notable Labs, Ltd. (NTBL) Healthcare & Pipeline Overview

Notable Labs, Ltd. is a clinical-stage biotechnology company leveraging its Predictive Precision Medicines Platform (PPMP) to develop targeted cancer therapies. The company's platform bio-simulates treatments to predict patient response, aiming to optimize clinical development for indications like acute myeloid leukemia and myelodysplastic syndromes.

What Is the Investment Thesis for NTBL?

Notable Labs, Ltd. presents a research focus centered on its proprietary Predictive Precision Medicines Platform (PPMP), which aims to revolutionize oncology drug development by identifying patient responders pre-treatment. This platform's capability to bio-simulate treatment responses could significantly de-risk clinical trials, potentially accelerating drug development timelines and improving success rates for pipeline assets like Volasertib and Fosciclopirox. Volasertib, a PLK-1 inhibitor, targets acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes, representing high-need indications. Fosciclopirox is also in development for AML. The company's strategy to select clinically responsive patients could lead to more efficient trials, potentially reducing the capital intensity typically associated with biotech R&D. However, as a clinical-stage company with a market capitalization of $2.39M and a profit margin of -3633.5%, Notable Labs faces substantial financial risks and requires significant future funding. Its beta of -2.36 indicates high volatility. The investment thesis hinges on the PPMP's validation through successful clinical outcomes and its potential to attract partnerships or secure future funding rounds.

Based on FMP financials and quantitative analysis

NTBL Key Highlights

• Market capitalization is $0.00B, reflecting its early-stage development and current valuation.
• Profit margin stands at -3633.5%, indicative of significant R&D expenses and lack of commercial revenue typical for a clinical-stage biotechnology company.
• Gross margin is 36.5%, though less relevant for a company primarily focused on research and development without substantial product sales.
• Beta is -2.36, suggesting a highly volatile stock with an inverse relationship to overall market movements, which is an unusual characteristic.
• The company operates with a lean team of 16 employees, focusing resources on its core R&D and platform development activities.

Who Are NTBL's Competitors?

NTBL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NTBL's Key Strengths?

• Proprietary Predictive Precision Medicines Platform (PPMP) offering a unique approach to patient selection.
• Targeted pipeline assets (Volasertib, Fosciclopirox) addressing high-need oncology indications.
• Potential for faster and more efficient clinical development by identifying responsive patients.
• Focus on precision medicine aligns with a growing trend in oncology.

What Are NTBL's Weaknesses?

• Clinical-stage company with no approved products or commercial revenue.
• Significant operating losses, as evidenced by a -3633.5% profit margin.
• Small team of 16 employees, potentially limiting breadth of R&D efforts.
• High beta of -2.36 indicates extreme volatility and potentially higher investment risk.

What Could Drive NTBL Stock Higher?

• Advancement of Volasertib into later-stage clinical trials for acute myeloid leukemia (AML), pediatric leukemia, or myelodysplastic syndromes (MDS), which could validate its therapeutic potential.
• Positive data readouts from ongoing clinical studies for Fosciclopirox in acute myeloid leukemia (AML), demonstrating efficacy and safety.
• Formation of strategic partnerships or licensing agreements for the Predictive Precision Medicines Platform (PPMP) or its pipeline assets, providing external validation and funding.
• Continued development and refinement of the proprietary Predictive Precision Medicines Platform (PPMP) to enhance its predictive capabilities and expand its applications.

What Are the Key Risks for NTBL?

• Financial-distress signal — its Altman Z-Score of -15.31 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-60.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• High research and development costs coupled with significant operating losses, as evidenced by a -3633.5% profit margin, which is typical for clinical-stage biotechnology companies.
• Clinical trial failures for Volasertib or Fosciclopirox, which could lead to substantial delays, increased costs, or the complete termination of development programs.
• Stringent regulatory hurdles and lengthy approval processes inherent in the pharmaceutical industry, potentially impacting the timeline and cost of bringing new therapies to market.
• Intense competition within the oncology therapeutics market from established pharmaceutical companies and other biotechnology firms developing similar or alternative cancer treatments.
• Dependence on securing additional funding to support ongoing research and development activities and clinical trials, given its current financial profile and lack of commercial revenue.

What Are the Growth Opportunities for NTBL?

• Expansion of PPMP Applications: The Predictive Precision Medicines Platform (PPMP) currently focuses on specific cancer indications, but its underlying technology has broader applicability. Notable Labs could expand the platform's utility to encompass a wider range of cancer types, including solid tumors, or even explore non-oncology therapeutic areas where patient response prediction is critical. This expansion could significantly enlarge the addressable market for the PPMP, potentially attracting new research collaborations or licensing opportunities. The market for precision medicine diagnostics and therapeutics is projected to grow substantially, offering a fertile ground for platform diversification over the next 5-10 years.
• Pipeline Advancement and Commercialization: The successful progression of Volasertib and Fosciclopirox through clinical trials represents a primary growth driver. Positive data readouts, especially from later-stage trials, would significantly de-risk these assets and increase their commercial potential. Achieving regulatory approvals for acute myeloid leukemia (AML), pediatric leukemia, or myelodysplastic syndromes (MDS) would transition Notable Labs from a clinical-stage to a commercial-stage company, generating revenue. The global market for AML treatments alone is estimated to reach several billion dollars annually, providing a substantial target for these therapies within a 3-7 year timeframe, contingent on trial success.
• Strategic Partnerships and Licensing: Given its clinical-stage nature and proprietary platform, Notable Labs has a significant opportunity to forge strategic alliances with larger pharmaceutical companies. These partnerships could provide crucial funding, access to broader R&D resources, and established commercialization infrastructure for its pipeline assets or the PPMP technology itself. Licensing agreements for specific drug candidates or the platform's use in new indications could generate upfront payments and milestone revenues, providing non-dilutive capital and validating the technology. Such collaborations could materialize within the next 2-4 years, accelerating development and market reach.
• Leveraging PPMP for Novel Drug Discovery: Beyond its current pipeline, the Predictive Precision Medicines Platform could be leveraged as a powerful tool for novel drug discovery and development. By accurately predicting patient response, the platform could identify new therapeutic targets, optimize drug candidates, or even facilitate the repurposing of existing drugs for new indications. This data-driven approach could lead to a more efficient and targeted drug discovery process, potentially yielding a robust future pipeline. This long-term opportunity, spanning 5-10 years, positions Notable Labs as an innovator in identifying effective treatments with higher probability of success.
• Geographic Market Expansion: While Notable Labs is headquartered in Foster City, California, and Or-Yehuda, Israel, the global oncology market offers significant opportunities for expansion. Once pipeline assets achieve regulatory approval in initial markets, pursuing approvals and commercialization in other major pharmaceutical markets, such as Europe, Asia-Pacific, and other developed regions, could substantially increase revenue potential. This would involve navigating diverse regulatory landscapes and establishing distribution networks, potentially through partnerships. This growth vector would likely follow initial market entry, typically within 5-10 years post-first approval.

What Opportunities Does NTBL Have?

• Expansion of the PPMP's application to a broader range of cancer types or therapeutic areas.
• Successful advancement of Volasertib and Fosciclopirox through later-stage clinical trials.
• Formation of strategic partnerships or licensing agreements with larger pharmaceutical companies.
• Leveraging the PPMP for novel drug discovery and pipeline expansion beyond current candidates.

What Threats Does NTBL Face?

• High risk of clinical trial failures, which could lead to substantial program delays or termination.
• Intense competition within the oncology therapeutics market from established players and other biotech firms.
• Significant regulatory hurdles and lengthy approval processes inherent in drug development.
• Ongoing need for substantial funding to support R&D, potentially leading to future dilution or financing challenges.

What Are NTBL's Competitive Advantages?

• Proprietary Predictive Precision Medicines Platform (PPMP) for bio-simulating treatment responses.
• Specialized expertise in identifying clinically responsive cancer patients prior to treatment.
• Pipeline of novel drug candidates (Volasertib and Fosciclopirox) targeting specific oncology indications.
• Potential to enhance clinical trial success rates and accelerate drug development timelines through patient pre-selection.

What Does NTBL Do?

Notable Labs, Ltd. is a clinical-stage platform therapeutics company dedicated to advancing predictive precision medicines for cancer patients. Headquartered in Foster City, California, the company operates within the high-innovation biotechnology sector, focusing on addressing significant unmet medical needs in oncology. At the core of Notable Labs' strategy is its proprietary Predictive Precision Medicines Platform (PPMP). This advanced platform is engineered to bio-simulate the effects of a cancer treatment and subsequently predict whether an individual patient is likely to respond to that specific therapeutic intervention. The fundamental objective of the PPMP is to identify and select clinically responsive patients prior to the commencement of their treatment. This capability is designed not only to optimize patient outcomes by guiding treatment decisions but also to significantly fast-track clinical development processes within these targeted patient populations. By pre-screening for responders, Notable Labs aims to increase the efficiency and success rates of its clinical trials, potentially reducing the time and cost associated with bringing new therapies to market. The company's pipeline currently features two key assets. Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor, is under development for multiple indications, including acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes (MDS). These are aggressive blood cancers with significant treatment challenges, highlighting Notable Labs' focus on severe diseases. The second asset, Fosciclopirox, is a pro-drug of ciclopirox, also being developed for acute myeloid leukemia (AML). Both pipeline candidates represent targeted approaches, aligning with the company's overarching precision medicine strategy. Notable Labs, with its team of 16 employees, positions itself at the forefront of personalized oncology, striving to transform cancer treatment paradigms by ensuring that the right patient receives the right therapy at the right time. The company's evolution is centered on leveraging its technological platform to de-risk drug development and deliver more effective treatments.

What Products and Services Does NTBL Offer?

• Develops predictive precision medicines specifically for patients with cancer.
• Utilizes a proprietary Predictive Precision Medicines Platform (PPMP) to guide treatment decisions.
• Bio-simulates cancer treatments to predict patient response to specific therapeutics.
• Identifies and selects clinically responsive patients prior to their treatment.
• Aims to fast-track clinical development in targeted patient populations.
• Advances Volasertib, a PLK-1 inhibitor, for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes (MDS).
• Develops Fosciclopirox, a pro-drug of ciclopirox, for acute myeloid leukemia (AML).
• Focuses on improving the efficiency and success rates of oncology clinical trials.

How Does NTBL Make Money?

• Primarily engaged in research and development (R&D) and clinical-stage drug development.
• Aims to generate future revenue through the commercialization of its proprietary drug candidates upon regulatory approval.
• Seeks to establish strategic partnerships and licensing agreements for its Predictive Precision Medicines Platform (PPMP) or pipeline assets.
• Focuses on reducing clinical trial costs and accelerating market entry by identifying patient responders early in the development process.

What Industry Does NTBL Operate In?

Notable Labs, Ltd. operates within the highly dynamic and innovation-driven biotechnology industry, specifically focusing on the oncology therapeutics sector. This industry is characterized by significant R&D investment, lengthy development cycles, and substantial regulatory hurdles, yet it offers immense potential for addressing critical unmet medical needs. A key trend shaping the landscape is the shift towards precision medicine and personalized oncology, where treatments are tailored based on individual patient characteristics, often guided by biomarkers or predictive platforms. Notable Labs' Predictive Precision Medicines Platform (PPMP) positions it directly within this trend, aiming to improve treatment efficacy and reduce trial failures by pre-selecting responsive patients. The competitive landscape is intense, featuring both large pharmaceutical companies with extensive resources and numerous smaller, specialized biotech firms. Notable Labs differentiates itself through its unique predictive platform, which seeks to optimize patient selection, a critical factor in the success of targeted therapies. The company's clinical-stage status means it is currently focused on R&D, with future success dependent on advancing its pipeline through rigorous clinical trials and securing regulatory approvals in a market demanding innovative cancer solutions.

Who Are NTBL's Key Customers?

• Currently, as a clinical-stage company, Notable Labs does not have direct commercial customers.
• Future customers will include cancer patients requiring targeted therapies for indications like AML, pediatric leukemia, and MDS.
• Oncologists and healthcare providers who prescribe advanced cancer treatments.
• Potential pharmaceutical partners for co-development, licensing, or commercialization of its platform or drug candidates.

FY2026 estForward Outlook

Wall Street analysts project Notable Labs, Ltd. revenue of about $1.2M for fiscal 2026, with EPS near $-1.30.

F-Score 1/9Financial Health

Notable Labs, Ltd.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.31 places it in the distress zone, a signal of elevated financial risk.

ROE -60%Key Financial Metrics

Return on equity for Notable Labs, Ltd. stands at -60.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -57.6%, showing how much profit it generates from its asset base. A current ratio of 5.65 indicates the company holds enough short-term assets to cover its near-term obligations.

Notable Labs, Ltd. (NTBL) Valuation Context

Valued at $2.39M, NTBL is classified as a micro-cap stock. Relative to its peer group, NTBL's quantitative score of 64/100 is roughly in line with the peer average of 73/100.

Company Profile

Notable Labs, Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Or-Yehuda, IL. The company is led by CEO Kaile Zagger. NTBL has traded publicly since 2014.

NTBL Financials

NTBL Latest News

NTBL Analyst Consensus

NTBL MoonshotScore

Common Questions About NTBL (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources